JP7212615B2 - 多能性幹細胞からｈｌａホモ接合免疫細胞への指向分化方法 - Google Patents

多能性幹細胞からｈｌａホモ接合免疫細胞への指向分化方法 Download PDF

Info

Publication number
JP7212615B2
JP7212615B2 JP2019518229A JP2019518229A JP7212615B2 JP 7212615 B2 JP7212615 B2 JP 7212615B2 JP 2019518229 A JP2019518229 A JP 2019518229A JP 2019518229 A JP2019518229 A JP 2019518229A JP 7212615 B2 JP7212615 B2 JP 7212615B2
Authority
JP
Japan
Prior art keywords
cells
cell
hla
differentiation
hpcs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019518229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528771A (ja
JP2019528771A5 (https=
Inventor
マクシム エイ ボドヤニク
シン ツァン
アンドリュー ジェイ ブランドル
ディーピカ ラジェシュ
ブラッドリー スワンソン
クリスティー マン
サラ バートン
ウェン ボ ワン
Original Assignee
フジフィルム セルラー ダイナミクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フジフィルム セルラー ダイナミクス，インコーポレイテッド filed Critical フジフィルム セルラー ダイナミクス，インコーポレイテッド
Publication of JP2019528771A publication Critical patent/JP2019528771A/ja
Publication of JP2019528771A5 publication Critical patent/JP2019528771A5/ja
Priority to JP2022034065A priority Critical patent/JP7560502B2/ja
Application granted granted Critical
Publication of JP7212615B2 publication Critical patent/JP7212615B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2019518229A 2016-10-05 2017-10-05 多能性幹細胞からｈｌａホモ接合免疫細胞への指向分化方法 Active JP7212615B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022034065A JP7560502B2 (ja) 2016-10-05 2022-03-07 多能性幹細胞からｈｌａホモ接合免疫細胞への指向分化方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662404470P 2016-10-05 2016-10-05
US62/404,470 2016-10-05
US201762486895P 2017-04-18 2017-04-18
US62/486,895 2017-04-18
PCT/US2017/055369 WO2018067836A1 (en) 2016-10-05 2017-10-05 Methods for directed differentiation of pluripotent stem cells to hla homozygous immune cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022034065A Division JP7560502B2 (ja) 2016-10-05 2022-03-07 多能性幹細胞からｈｌａホモ接合免疫細胞への指向分化方法

Publications (3)

Publication Number Publication Date
JP2019528771A JP2019528771A (ja) 2019-10-17
JP2019528771A5 JP2019528771A5 (https=) 2020-11-12
JP7212615B2 true JP7212615B2 (ja) 2023-01-25

Family

ID=60302439

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019518229A Active JP7212615B2 (ja) 2016-10-05 2017-10-05 多能性幹細胞からｈｌａホモ接合免疫細胞への指向分化方法
JP2022034065A Active JP7560502B2 (ja) 2016-10-05 2022-03-07 多能性幹細胞からｈｌａホモ接合免疫細胞への指向分化方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022034065A Active JP7560502B2 (ja) 2016-10-05 2022-03-07 多能性幹細胞からｈｌａホモ接合免疫細胞への指向分化方法

Country Status (13)

Country Link
US (1) US20200263139A1 (https=)
EP (1) EP3523423B1 (https=)
JP (2) JP7212615B2 (https=)
KR (1) KR102598351B1 (https=)
CN (1) CN110023491B (https=)
AU (1) AU2017340644B2 (https=)
BR (1) BR112019006910A2 (https=)
CA (1) CA3038701A1 (https=)
DK (1) DK3523423T3 (https=)
ES (1) ES2989469T3 (https=)
IL (1) IL265810B2 (https=)
MX (1) MX2019003689A (https=)
WO (1) WO2018067836A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3177929A1 (en) 2012-12-21 2014-06-26 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
CN108431211B (zh) 2015-10-20 2026-03-24 富士胶片细胞动力公司 通过遗传编程的多谱系造血前体细胞产生
JP7212615B2 (ja) * 2016-10-05 2023-01-25 フジフィルム セルラー ダイナミクス，インコーポレイテッド 多能性幹細胞からｈｌａホモ接合免疫細胞への指向分化方法
WO2018195175A1 (en) 2017-04-18 2018-10-25 FUJIFILM Cellular Dynamics, Inc. Antigen-specific immune effector cells
WO2019094614A1 (en) * 2017-11-08 2019-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing hematopoietic progenitor cells in vitro
CA3130442A1 (en) * 2019-02-24 2020-08-27 Gamida Cell Ltd. Method of homing and retention of gammadelta t cells for generating cell compositions for use in therapy
CN110106144B (zh) * 2019-05-17 2021-10-08 苏州大学 一种诱导造血干细胞向前t系细胞分化的方法和试剂盒
CN110564691A (zh) * 2019-07-19 2019-12-13 青岛华赛伯曼医学细胞生物有限公司 Hla纯合子来源的通用型car-t细胞的制备方法
EP4176046A4 (en) * 2020-07-02 2024-07-31 Accellta Ltd. PLURIPOTENT STEM CELLS FROM MAMMALIAN CATTLE FROM DELAYED EMBRYOS
CN111808812B (zh) * 2020-08-31 2020-12-15 首都医科大学附属北京友谊医院 一种用于多能干细胞向造血干细胞分化的材料和方法
MX2023011927A (es) 2021-04-07 2023-10-23 Century Therapeutics Inc Composiciones y metodos para la generacion de linfocitos t gamma-delta a partir de celulas madre pluripotentes inducidas.
US20220333074A1 (en) 2021-04-07 2022-10-20 Century Therapeutics, Inc. Compositions and Methods for Generating Alpha-Beta T Cells from Induced Pluripotent Stem Cells
CN117957313A (zh) * 2021-07-19 2024-04-30 修复免疫股份有限公司 从多能干细胞生产免疫细胞群的方法
CN114324126B (zh) * 2022-01-07 2024-03-19 南京鼓楼医院 一种改变早期b细胞分化的方法
CN115896016B (zh) * 2022-09-07 2023-09-12 普华赛尔生物医疗科技有限公司 培养组合物及其在培养免疫细胞中的应用
JP2025533907A (ja) * 2022-10-05 2025-10-09 ガルーダ セラピューティクス， インコーポレイテッド 多能性細胞に由来する骨髄系統
WO2024077159A1 (en) * 2022-10-05 2024-04-11 Garuda Therapeutics, Inc. B cell lineages derived from pluripotent cells
WO2024101919A1 (ko) * 2022-11-10 2024-05-16 의료법인 성광의료재단 전분화능 줄기세포에서 자연살해세포로의 분화 유도용 배지 조성물 및 이를 이용한 분화 방법
CN120283045A (zh) * 2022-12-02 2025-07-08 安徽中盛溯源生物科技有限公司 用于扩增中脑多巴胺能祖细胞的培养基、包被基质和方法
WO2024220976A2 (en) * 2023-04-21 2024-10-24 New York Blood Center, Inc. Patrolling monocyte cellular therapy
CN117050941B (zh) * 2023-10-11 2024-01-26 苏州艾凯利元生物科技有限公司 一种制备自然杀伤细胞的方法
KR102921286B1 (ko) * 2024-02-23 2026-02-04 ㈜바이오솔빅스 Op9 세포의 분비단백질을 이용한 cd34 양성 조혈모세포의 제조방법
WO2025237762A1 (en) * 2024-05-14 2025-11-20 Englmeier Ludwig Matched t-cells and myeloid cells from cell culture

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010099539A1 (en) 2009-02-27 2010-09-02 Cellular Dynamics International, Inc. Differentiation of pluripotent cells
JP2013501505A (ja) 2009-08-07 2013-01-17 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
WO2015164740A1 (en) 2014-04-24 2015-10-29 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
JP2016537337A (ja) 2013-11-13 2016-12-01 コーネル ユニヴァーシティ 生後の造血内皮細胞ならびにそれらの単離および使用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB2197915B (en) 1986-11-19 1990-11-14 Rolls Royce Plc Improvements in or relating to fluid bearings
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US5556954A (en) 1992-02-13 1996-09-17 Beth Israel Hospital Boston Association Hematopoietic stem cell specific gene expression
DE69334225D1 (de) 1992-07-07 2008-07-31 Japan Tobacco Inc Verfahren zur transformation einer monokotyledon pflanze
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
WO1994002620A2 (en) 1992-07-27 1994-02-03 Pioneer Hi-Bred International, Inc. An improved method of agrobacterium-mediated transformation of cultured soybean cells
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
AU5389096A (en) 1996-04-11 1997-10-29 Human Genome Sciences, Inc. Human hematopoietic-specific protein
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
DE10224242A1 (de) 2002-05-29 2003-12-11 Max Delbrueck Centrum Frog Prince, ein Transposonvektor für den Gentransfer bei Wirbeltieren
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
US7606580B2 (en) 2005-05-11 2009-10-20 Aol Llc Personalized location information for mobile devices
JPWO2007049749A1 (ja) 2005-10-28 2009-04-30 ディナベック株式会社 血液凝固異常の治療方法
EP2712921B1 (en) * 2008-05-06 2018-07-11 Astellas Institute for Regenerative Medicine Hemangio colony forming cells and non-engrafting hemangio cells
AU2015200413B2 (en) * 2009-06-05 2017-08-24 FUJIFILM Cellular Dynamics, Inc. Reprogramming t cells and hematopoietic cells
DK2438160T3 (en) 2009-06-05 2016-01-11 Cellular Dynamics Int Inc Reprogramming of T cells and hematopoietic cells
US8464599B2 (en) 2011-01-10 2013-06-18 GM Global Technology Operations LLC Eight speed dual clutch transmission
JP6677631B2 (ja) * 2013-03-13 2020-04-08 ウイスコンシン アラムナイ リサーチ ファウンデーシヨンＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 定義された条件下におけるヒト多能性幹細胞の造血内皮分化のための方法及び材料
AU2014248119B2 (en) * 2013-04-03 2019-06-20 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
WO2015057261A1 (en) * 2013-10-16 2015-04-23 The Brigham And Women's Hospital, Inc. Methods of generating intermediate mesoderm cells from human pluripotent stem cells
BR112016028537A2 (pt) * 2014-06-04 2017-08-22 Hutchinson Fred Cancer Res expansão e enxerto de células-tronco utilizando agonistas de notch 1 e/ou de notch 2
JP7212615B2 (ja) 2016-10-05 2023-01-25 フジフィルム セルラー ダイナミクス，インコーポレイテッド 多能性幹細胞からｈｌａホモ接合免疫細胞への指向分化方法
WO2018195175A1 (en) * 2017-04-18 2018-10-25 FUJIFILM Cellular Dynamics, Inc. Antigen-specific immune effector cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010099539A1 (en) 2009-02-27 2010-09-02 Cellular Dynamics International, Inc. Differentiation of pluripotent cells
JP2013501505A (ja) 2009-08-07 2013-01-17 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
JP2016537337A (ja) 2013-11-13 2016-12-01 コーネル ユニヴァーシティ 生後の造血内皮細胞ならびにそれらの単離および使用
WO2015164740A1 (en) 2014-04-24 2015-10-29 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products

Also Published As

Publication number Publication date
WO2018067836A1 (en) 2018-04-12
CA3038701A1 (en) 2018-04-12
BR112019006910A2 (pt) 2019-07-02
IL265810B1 (en) 2024-04-01
JP2019528771A (ja) 2019-10-17
KR102598351B1 (ko) 2023-11-08
JP7560502B2 (ja) 2024-10-02
MX2019003689A (es) 2019-08-22
CN110023491A (zh) 2019-07-16
AU2017340644B2 (en) 2024-05-09
CN110023491B (zh) 2024-03-08
ES2989469T3 (es) 2024-11-26
IL265810B2 (en) 2024-08-01
DK3523423T3 (da) 2024-09-02
EP3523423A1 (en) 2019-08-14
KR20190057387A (ko) 2019-05-28
US20200263139A1 (en) 2020-08-20
AU2017340644A1 (en) 2019-04-18
IL265810A (en) 2019-06-30
EP3523423B1 (en) 2024-07-31
JP2022078215A (ja) 2022-05-24

Similar Documents

Publication Publication Date Title
JP7560502B2 (ja) 多能性幹細胞からｈｌａホモ接合免疫細胞への指向分化方法
US12129486B2 (en) Methods for directed differentiation of pluripotent stem cells to immune cells
EP3612557B1 (en) Antigen-specific immune effector cells
JP2018531025A6 (ja) 多能性幹細胞の免疫細胞への分化を誘導する方法
US20260097074A1 (en) Erythroid lineages derived from pluripotent cells
US20260103680A1 (en) Pluripotent stem cell-derived megakaryocytes and platelets
US20250368955A1 (en) B cell lineages derived from pluripotent cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220307

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221202

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221202

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221208

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221227

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230113

R150 Certificate of patent or registration of utility model

Ref document number: 7212615

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250